BUZZ-Tarsus Pharma slides on $100 mln stock offering
I'm PortAI, I can summarize articles.
Tarsus Pharmaceuticals' stock slides after a $100 million stock offering. The offering price represents a 16.3% discount to the stock's last close. The company plans to use the proceeds for the commercial launch of Xdemvy and the development of its dermatology and infectious disease prevention product pipeline. Tarsus shares have risen nearly 90% YTD and have gained 150% over the past 12 months.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments